Abstract
Rationale Outcomes in patients with severe SARS-CoV-2 infection (COVID-19) are conditioned by virus clearance and regulation of inflammation. Variants in IFIH1, a gene coding the cytoplasmatic RNA sensor MDA5, regulate the response to viral infections.
Objective To characterize the impact of IFIH1 rs199076 variants on host response and outcomes after severe COVID-19.
Methods Patients admitted to an intensive care unit (ICU) with confirmed COVID-19 were prospectively studied and rs1990760 variants determined. Peripheral blood gene expression, cell populations and immune mediators were measured. Peripheral blood mononuclear cells from healthy volunteers were exposed to an MDA5 agonist and dexamethasone ex-vivo, and changes in gene expression assessed. ICU discharge and hospital death were modelled using rs1990760 variants and dexamethasone as factors in this cohort and in-silico clinical trials.
Measurements and Main Results 227 patients were studied. Patients with the IFIH1 rs1990760 TT variant showed a lower expression of inflammation-related pathways, an anti-inflammatory cell profile and lower concentrations of pro-inflammatory mediators. Cells with TT variant exposed to a MDA5 agonist showed an increase in IL6 expression after dexamethasone treatment. All patients with the TT variant not treated with steroids (N=14) survived their ICU stay (HR 2.49, 95% confidence interval 1.29–4.79). Patients with a TT variant treated with dexamethasone (N=50) showed an increased hospital mortality (HR 2.19, 95% confidence interval 1.01–4.87) and serum IL-6. In-silico clinical trials supported these findings.
Conclusions COVID-19 patients with the IFIH1 rs1990760 TT variant show an attenuated inflammatory response and better outcomes. Dexamethasone may reverse this anti-inflammatory phenotype.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Prospective observational study, no trial ID required.
Funding Statement
Supported by Centro de Investigacion Biomedica en Red (CB17/06/00021), Instituto de Salud Carlos III (grant numbers PI19/00184 and PI20/01360) and Fundacio La Marato de TV3 (grant 413/C/2021). Instituto Universitario de Oncologia is supported by Fundacion Liberbank. RRG is the recipient of a grant from Instituto de Salud Carlos III (CM20/00083).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This single-center prospective, observational study was approved (ref. 2020/188) by the Clinical Research Ethics Committee of Principado de Asturias (Spain). Informed consent was obtained from each participant or next of kin.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding Supported by Centro de Investigación Biomédica en Red (CB17/06/00021), Instituto de Salud Carlos III (grant numbers PI19/00184 and PI20/01360) and Fundació La Marató de TV3 (grant 413/C/2021). Instituto Universitario de Oncología is supported by Fundación Liberbank. RRG is the recipient of a grant from Instituto de Salud Carlos III (CM20/00083).
Declaration of interests None of the authors report a conflict of interest.
Data Availability
RNA-seq data has been deposited in Gene Expression Omnibus (accession numbers GSE168400 and GSE177025). Code for in-silico clinical trials is available at https://github.com/Crit-Lab/IFIH1_simulation. De-identified clinical data will be shared with researchers with any proposal after review and approval by the local Ethics Committee and a signed data access agreement. R code used for statistical analyses is also available on request. All requests should be sent to the corresponding author (gma{at}crit-lab.org).
https://github.com/Crit-Lab/IFIH1_simulation
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE168400
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE177025
